Core Viewpoint - Xilong Health (002105.SZ) expects a net profit attributable to shareholders of the listed company to be between -80 million and -55 million yuan for 2025, representing a year-on-year decline of 322.52% to 190.48% [1] Financial Performance - The company's operating revenue remained roughly flat compared to the previous year, but losses increased significantly [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -87 million and -62 million yuan [1] Reasons for Loss Increase - The decline in export revenue due to international market conditions and tariff changes, despite a year-on-year increase in domestic sales [1] - A decrease in gross profit margin due to intense market competition, leading to reduced gross profit [1] - The appreciation of the RMB against the USD by over 2% this year resulted in a decrease in the RMB amount of export revenue, further reducing gross profit, along with an increase in financial expenses due to exchange losses of over 6 million yuan [1] - The price of aluminum, the company's main raw material, increased by approximately 4% during the year, reaching historical highs, which led to a rise in operating costs [1] - The company plans to recognize a single impairment provision of approximately 12 million yuan for long-term equity investments and other receivables based on the valuation of a share transaction for its associate company, Tianteng Power, in 2025 [1]

Core Viewpoint - The company, Heyuan Bio (688238.SH), expects to reduce its net loss for the year 2025, projecting a net profit attributable to shareholders of between -237 million to -195 million yuan, representing a reduction in loss of 84.81 million to 127 million yuan compared to the previous year, with a decrease in loss margin of 26.35% to 39.41% [1] Financial Projections - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -244 million to -201 million yuan, which indicates a reduction in loss of 91.91 million to 135 million yuan compared to the previous year, with a decrease in loss margin of 27.36% to 40.16% [1]

Core Viewpoint - Strongly New Materials (300429.SZ) expects a loss of 100 million to 142 million yuan in 2025, a decrease from the previous year's loss of 181.693 million yuan, indicating an improvement in financial performance despite ongoing challenges [1] Financial Performance - The company reported a loss for the current reporting period, but the loss has decreased compared to the previous year [1] - The expected non-recurring gains and losses will impact net profit by approximately 5.5 million to 8 million yuan [1] Factors Influencing Performance - Market demand and competitive environment have led to a recovery in gross profit during the reporting period [1] - Research and development expenses have increased during the current reporting period [1] - The company plans to recognize inventory impairment losses of 27.3 million yuan and non-current asset impairment losses of 51.2 million yuan [1]

广安爱众(600979)1月23日公告，预计2025年度实现归属于母公司所有者的净利润亏损3亿元—5.2亿元。 受气候因素影响，公司水电站来水量同比减少，且自2025年8月起执行居民生活用电低谷电价政策，自 供区售电均价下降。 ...

报告期内，受市场环境因素影响，公司主营业务订单达成不及预期，导致公司营业收入较去年同期出现 下滑，另一方面，为增强核心竞争力，公司在新产品研发及产业链布局等方面仍保持较高投入，而新产 品市场推广尚未形成规模贡献，预计公司2025年度将出现亏损。公司核心竞争力和持续经营能力未发生 重大不利变化。 格隆汇1月23日丨多伦科技(603528.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司 所有者的净利润-2,500万元，与上年同期相比，将出现亏损。预计2025年年度实现归属于母公司所有者 的扣除非经常性损益后的净利润-8,000万元。 ...

济民健康公告，预计2025年度归属于母公司所有者的净利润为亏损2.1亿元到2.5亿元，上年同期为亏损 5971.17万元。报告期内，受美国关税政策和"何清红私刻印章事件"等因素的影响，公司收入进一步下 滑，导致公司亏损进一步增加。 ...

格隆汇1月22日｜盈方微公告，预计归属于上市公司股东的净利润为-6900万元至-9700万元。上年同期 为-6197.04万元。报告期内，公司分销业务部分产品销售价格下降，新产品线处于开拓阶段毛利较低， 整体毛利率下滑；同时因实施股权激励确认股份支付费用、确认财务利息费用及计提商誉减值准备导致 利润亏损。 ...

公告指出，公司预计2025年年度归属于上市公司股东的净利润出现亏损，主要受以下因素的综合影响：首先，受行业 竞争加剧等因素影响，公司营业收入同比减少，导致利润相应减少。此外，为了应对激烈的市场竞争，公司持续开拓 市场和销售渠道，管理费用和销售费用等期间费用发生较多。 （企业公告） 1月19日，惠发食品发布公告称，公司预计2025年度净亏损6200万元至7500万元，上年同期净亏损1658.59万元。 ...

Core Viewpoint - Anzheng Fashion (603839.SH) is expected to continue incurring losses in 2025, with projected net profit attributable to shareholders ranging from -130 million to -210 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -140 million and -220 million yuan for the year 2025 [1]

格隆汇1月19日丨渤海化学(600800.SH)公布，经财务部门初步测算，预计2025年年度实现归属于上市公 司股东的净利润约为-66,500万元到-63,200万元。预计2025年年度实现归属于上市公司股东扣除非经常 性损益后的净利润约为-79,900万元到-75,900万元。 ...